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Summary
Mast cell development is a complex process that results in the appearance of phenotypically distinct
populations of mast cells in different anatomical sites. Mice homozygous for mutations at the
W or Sl locus exhibit several phenotypic abnormalities, including a virtual absence of mast cells
in all organs and tissues. Recent work indicates that Wencodes thec-kittyrosine kinase receptor,
whereas Sl encodes a c-kitligand that we have designated stem cell factor (SCF). Recombinant
or purified natural forms of the c-kitligand induce proliferation of certain mast cell populations
in vitro, and injection of recombinant SCF permits mast cells to develop in mast cell-deficient
WCB6Ft-SI/Sld mice. However, the effects of SCF on mast cell proliferation, maturation, and
phenotype in normal mice in vivo were not investigated. We now report that localadministration
of SCF in vivo promotes the development of connective tissue-type mast cells (CTMC) in the
skin of mice and that systemic administration of SCF induces the development of both CTMC
and mucosal mast cells (MMC) in rats. Rats treated with SCF also develop significantly increased
tissue levels of specific rat mast cell proteases (RMCP) characteristic of either CTMC (RMCP
I) or MMC (RMCP II). These findings demonstrate that SCF can induce the expansion of both
CTMC and MMC populations in vivo and show that SCF can regulate at least one cellular
lineage that expresses c-kit, the mast cell, through complex effects on proliferation and maturation.
S
tudies in mice and rats indicate that mast cells are derived
from hematopoietic precursors that arise in the bone
marrow and circulate in the blood, but complete their pro-
gram of differentiation and maturation within interstitial
tissues, epithelia, or serosal cavities (reviewed in references
1-6). In murine rodents, this process results in the genera-
tion of at least two distinct mast cell populations that vary
in many aspects ofphenotype, the connective tissue-type mast
cells (CTMC)t, which occur in such sites as the skin and
peritoneal cavity, and the mucosal mast cells(MMC), which
occur in the mucosa of the gastrointestinal tract (reviewed
in references 1-4). Evidence derived from both in vitro and
in vivo studies indicates that IIr3 represents one major growth
1 Abbreviations used in this paper. BrdU, 5-bromo-2'-deoxyuridine; CTMC,
connective tissue-type mast cell; Hct, hematocrit; MMC, mucosal mast
cell; PMC, peritoneal mast cell; RMCP, rat mast cell protease; rrSCF164,
recombinant rat stem cell factort64.
factor for MMC, whereas the regulation of CTMC prolifer-
ation requires additional and/or alternative factors (reviewed
in references 1-6). For example, in vitro work indicates that
one representative CTMC, peritoneal mast cells (PMC), do
not proliferate in response to IIr3 alone but divide when 11,3
is provided with a second stimulus such as IIT4 (7) or PMA (8).
Several important insights into mast cell development have
been derived from analyses of mice that virtually lack mast
cells as a result of a double dose of mutant genes at either
the W locus on chromosome 5 or the SI locus on chromo-
some 10 (reviewed in references 1, 2, and 5). For example,
W or Sl mutant mice lack both CTMC and MMC, indi-
cating that the W or Sl gene products are important in the
development of both of these mast cell populations in vivo
(reviewed in references 1, 2, 5, and 6). Moreover, both in
vitro and in vivo studies suggested that the mast cell deficien-
cies of these mutant mice reflected, in the case of W mu-
tants, defects in the responsiveness of cells in the mast cell
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Volume 174 July 1991 125-131lineage to a stromal cell-derived growth factor and, in the
case ofSl mutants, inadequate production of this growth factor
by stromal cells (reviewed in references 1, 2, and 5).
The products encoded at W and Sl recently have been
defined. W encodes the c-kit tyrosine kinase growth factor
receptor (9, 10), whereas Sl encodes a newly recognized mul-
tifunctional growth factor that represents a ligand for c-kit
(11-18). Several lines of evidence in addition to the lack of
mast cells in W or Sl mutant mice indicate that one of the
important biological activities of the c-kitligand is to regu-
late mast cell development. The recombinant c-kitligand can
promote the proliferation of certain populations of imma-
ture, IIr3-dependent mast cells in vitro (11, 14, 15, 17, 18),
and the c-kit ligand purified from the supernatants of
BALB/3T3 fibroblasts (19), or the recombinant ligand (20),
can induce proliferation of IL-3-independent mouse PMC in
vitro. In addition, we demonstrated that daily subcutaneous
injection of a recombinant c-kit ligand, recombinant rat stem
cell factor
164 (rrSCF164), for 3 wk permitted mast cells to de-
velop in the skin of genetically mast cell-deficient WCB6F1-
Sl/Sld mice (16). However, the mast cells that developed in
WCB6Ft-Sl/Sld mice injected with rrSCF164 were not char-
acterized according to phenotype. Nor was it determined
whether rrSCF164 could influence mast cell development or
phenotype in normal mice. In the present study, we there-
fore examined the effects of rrSCF164 on mast cell popula-
tions in normal mice and rats in vivo, using approaches that
permitted the anatomical and phenotypic characterization of
the respondingcells as CTMC or MMC. Some ofthese results
have been reported in abstract form (20).
Materials and Methods
Studies in Mice.
￿
Groups of five to seven female 8-12-wk-old
WCB6F,-+/+, WCB6F,-Sl/Sld, WBB6F,-+/+, and WBB6F,-
WlWv mice (The Jackson Laboratory, Bar Harbor, ME) received
for 3 wk a daily subcutaneous injection of rrSCF161 purified from
Escherichiacoli and modified by the covalent attachment ofpolyeth-
ylene glycol (16) or vehicle alone (0, 30, or 100 Rg rrSCF16^/kg
in 150-200 Ftl of sterile saline containing 0.1% BSA) (fraction V,
fatty acid free; ICN Immunobiologicals, Lisle, IL). Injections were
performed with the mice under light ether anesthesia and were
delivered to approximately the same site on the dorsal back skin.
Blood for determination of hematocrit (Hct) was obtained from
the mice by retroorbital puncture under light ether anesthesia on
the day before initiation of treatment and on the day ofdeath. For
labeling of tissue mast cells proliferating in vivo (21), 5-bromo-2'-
deoxyuridine (BrdU) (Sigma Chemical Co., St. Louis, MO) was
injected intraperitoneally (100 mg/kg in sterile saline) 1 h before
death. After death by cervical dislocation, the cutaneous injection
site was excised and fixed in Carnoy's fixative, and embedded in
paraffin. 4-um sections were cut, placed onto polylysine-coated
slides, and processed as in reference 21 for staining of mast cells
with 1.0% alcian blue, pH 1.0, and for immunohistochemical
staining of BrdU-labeled nuclei, using an anti-BrdU mAb (Becton
Dickinson & Co., Mountain View, CA). The slides were exam-
ined at 400x to quantify mast cells/mm' of dermis (22) and to
determine the percent of mast cells positive for BrdU incorpora-
tion (21). Otherslides ofthe Camoy's-fixed specimens were stained
with the heparin-binding fluorescent dye berberine sulfate (23) or
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with alcian blue/safranin, and were examined in an epifluorescent
or light microscope, respectively, as previously described (1, 22).
Studies in Rats. Groups of five to eight female 16-wk-old
Wistar rats received 14-d daily intravenous injections of either
rrSCF'64 (25 wg/kg/d in 1.0 ml of sterile, pyrogen-free 0.9% NaCl
"saline") or 1.0 ml of saline alone. 24 h after the last injection,
the rats were killedby exsanguination under deep ether anesthesia,
and samples of tissues were fixed in 4.0% paraformaldehyde,
processed into paraffin, and assessed in sections stained with 0.5%
toluidine blue at pH 0.5 for 2 h (24). Mast cells were quantified
at 400x, and the results were expressed as no. (mean ±
SEM)/mmz of tissue (22). Other samples of the same tissues were
processed as described (24) for determination of content ofrat mast
cell protease I (RMCP I) and RMCP II by ELISA, and the results
were expressed as micrograms protease (mean ± SEM)/gram of
tissue. The bone marrow cells were harvested from a single femur
of each rat by flushing the marrow cavity with 0.9% NaCl and
then washing the cells three times with HBSS/5% FCS
(HBSS/FCS). The peritoneal lavage cells ofeach rat were obtained
by lavaging each peritoneal cavity with 20 ml of HBSS/FCS and
then washing the cells three times with HBSS/FCS. Aliquots of
the total femoral bone marrow cells and peritoneal lavage cells were
diluted 1:10 in methylene blue/propylene glycol for counting the
numbers of total cells and mast cells in each preparation, the re-
mainder of the femoral blue marrow or peritoneal cells were used
for determination of RMCP I and 11 content by ELISA (24).
Results and Discussion
Local Administration ofSCF Induces the c-kit-dependent De-
velopment of CTMC in the Skin ofMice. Recombinant rat
SCF164 administered in daily subcutaneous injections for 3
wk induced a striking expansion ofdermal mast cell popula-
tions in normal WBB6F1-+/+ or WCB6F1-+/+ mice, and
in genetically mast cell-deficient WCB6F1-Sl/Sld mice (Table
1) . In WBB6F1-+/+ mice, mast cell numbers at sites in-
jected with 100 or 30 hg of rrSCF164/kg were 166 or 15
times that in control sites injected with vehicle alone. In
striking contrast to its effects on populations of dermal mast
cells, rrSCFlsa had little or no effect on the Hct of normal
mice of either genotype tested (Table 1).
The majority of the mast cells at rrSCF161 injection sites,
like dermal CTMC in the skin of untreated normal mice (1,
22), exhibited cytoplasmic reactivity with the heparin-binding
fluorescent dye berberine sulfate, and many of them stained
with safranin (Fig. 1, A, B, D, and E). Thus, injection of
rrSCF164 as the sole exogenous cytokine resulted in the de-
velopment ofdermal mast cells with characteristics ofCTMC.
Colocalization of immunohistochemical staining for BrdU
incorporated into nuclear DNA and mast cell cytoplasmic
granule staining with alcian blue (21) indicated that mor-
phologically identifiable mast cellswere proliferating at sites
of rrSCF164 injection (Table 1 and Fig. 1 F) . This finding
indicated that the increased numbers of mast cells at sites of
rrSCF164 injection reflected at least in part the proliferation
of differentiated dermal mast cells, not merely the prolifera-
tion and/or maturation of mast cell precursors.
However, the skin of Sl/Sld mice ordinarily contains vir-
tually no dermal mast cells (Table 1 and reference 25). Thus,
even though many differentiated mast cells were proliferatingTable 1 .
￿
C-kit-dependent Stimulation of Proliferation of Mouse Dermal Mast Cells in vivo by rrSCF164
Hct
Mice were killed 24 h after the last of 21 daily subcutaneous injections of rrSCF164 or vehicle for assessment of the number of mast cells/mmz of
dermis at the injection site and for quantification of the percent of these mast cells that were proliferating, based on nuclear incorporation of BrdU
(See Materials and Methods) . All results are expressed as mean t SEM (n = 5-7) .
'p< 0.001 vs . value for mice treated with 0 tog/kg/d by Student's t test (two tailed) .
Figure 1. (A-C) Skin at sites injected daily for 3 wk with either
rrSCF164 or vehicle and then stained with berberine sulfate. (A) Vehicle
injection site in aWBB6F1-+/+ mouse exhibits only occasional brightly
fluorescent mast cells . (B) Site in a WBB6F,-+/+ mouse injected with
rrSCF164 (100 ug/kg) exhibits many mast cells. (C) Many berberine sul-
fate-positive mast cells in the skin of a WCB6F1-Sl/Sld mouse injected
with rrSCF164 (30 pg/kg) . (D andE) Low(D) and high (E) power views
of safranin-positive dermal mast cells at a rrSCF164 injection site (30
,ug/kg) in a WCB6F,-+/+ mouse . (F) A rrSCF164 (100 Aglkg) injec-
tion site in a WBB6F,-+/+ mouse that had received BrdU to label
proliferating cells . There are many mast cells (stained with alcian blue in
this preparation); four of these mast cells have nuclei that are positive (brown
immunoperoxidase reaction product) for BrdU (arrows) (A-C, E, andF;
x250 ; D:
￿
x 1,000) .
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at rrSCFt64 injection sites in Sl/Sld mice 3 wk after initia-
tion of treatment (Table 1), some of the effect of rrSCF164
in these mice must have reflected the recruitment, prolifera-
tion, and/or induction of maturation ofthe mast cell precursors
present in these animals (25) . An effect of rrSCF164 on mast
cell maturation is also supported by the finding that many
of the mast cells at rrSCF164 injection sites in Sl/Sld mice
stained with berberine sulfate (Fig. 1 C) or safranin (data not
shown), and by data indicating that rrSCFt64 can induce 11,
3-dependent bone marrow-derived cultured mast cells to ma-
ture and acquire phenotypic characteristics ofCTMC in vitro
(20, 26) .
In contrast to the effects of rrSCF114 in Sl/Sld mice, in-
jection of rrSCF164 into genetically mast cell-deficient
WBB6F,-W/W° mice influenced neither the profound mast
cell deficiency, nor the anemia, of these animals (Table 1) .
This result, together with work indicating that the W and
W° alleles encode c-kit products that express no (W) or
markedly diminished (W°) tyrosine kinase activity (27), in-
dicates that the ability of rrSCF164 to induce the develop-
ment of dermal CTMC in vivo requires that the rrSCF164
interacts with a functionally active c-kit receptor. The com-
plete failure of even very high doses of rrSCF164 to induce
cutaneous mast cell development in W/W° mice is also
noteworthy in light of reports that this mutant can develop
mature dermal mast cells in association with a chronic idio-
pathic dermatitis (22), in response to repeated epicutaneous
applications of PMA (28), or as a result of treatment with
1173 (29) . The results reported here indicate that the appear-
ance of mast cells in the skin of W/W° mice in these set-
tings probably does not reflect increased local production of
endogenous c-kit ligand, but instead may be due to other
Mouse genotype rrSCF164
Before
treatment
After
treatment Mast cells
BrdU'
(percent of mast cells)
,uglkgld q no./mm2 of dermis
WBB6F1-+ / + 100 48 ± 1 .3 50 ± 0.7 4,710 ± 1,190' 16 ± 2 .2*
30 50 ± 0.8 51 ± 0.3 454 ± 155* 13 ± 2.7*
0 51 ± 0.6 51 ± 0.5 31 ± 2 3.3 ± 1.2
WBB6F,-W/W° 100 39 ± 0.8 36 ± 3.4 0 -
30 40 ± 0.7 40 ± 2.5 0 -
0 40 ± 0.6 39 ± 0.2 0 -
WCB6F,-+ /+ 30 46 ± 0.8 44 ± 2 .7 122 ± 17* 36 ± 3 .5'
0 47 ± 0.3 44±0.4 29±5 4.9±0.7
WCB6F,-Sl/Sld 30 30 ± 1 .1 38 ± 1 .7* 61 ± 24* 29 ± 5 .7
0 30 ± 0.3 33 ± 0.6 0 -effects such as the activation of either alternative signaling
mechanisms or processes distal to the interaction between c-kit
and its ligand.
Systemic Administration ofSCFExpandsPopulations ofCTMC
and MMC in the Rat. Even though subcutaneous adminis-
tration of rrSCF164 increased the Hct of Sl/Sld mice (Table
1), the effects of rrSCF164 on mast cell populations were
most striking in the vicinity of the subcutaneous injection
sites. For example, no mast cells appeared in the skin con-
tralateral to rrSCF164 injection sites in Sl/Sld mice or in the
gastric tissues of these animals (data not shown) . To assess
the systemic effects of rrSCF164 on mast cell development
and phenotype, we turned to the rat. Daily intravenous in-
jections are more readily performed in rats than in mice. More
importantly, Huntley et al. (24) have reported highly sensi-
tive and specific ELISA methods for quantifying tissue con-
tent of mast cell-specific proteases associated with CTMC
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and MMC (RMCP I and RMCP II, respectively) in this
species.
We found that daily intravenous administration of
rrSCF164 to rats at a dose of 25 Ag/kg/d for 14 d increased
mast cell levels systemically and also produced striking in-
creases in levels of both types of rat mast cell-associated pro-
teases (Tables 2 and 3). In the skin, lung, and liver (Table
2), rrSCF164 treatment resulted in marked increases in
numbers of mast cells and in tissue content of the CTMC-
associated protease, RMCP 1, but no significant changes in
levels of the MMC-associated protease, RMCP II. In the
spleen, bone marrow, and peritoneal cavity (Tables 2 and 3),
rrSCF164 treatment resulted in striking expansion of mast
cell populations, as well as marked increases in levels ofboth
RMCPI and RMCPIl. Note, however, that the totalamounts
of RMCP II in these sites in the rrSCF164-treated animals
were much less than the corresponding amounts of RMCP
Rats were killed -24 h after the last injection of 14 daily intravenous injections of rrSCF164 or vehicle for assessment of mast cell numbers and
content of RMCP I and RMCP II in various tissues (See Materials and Methods). All results are expressed as mean ± SEM (n - 5-8) .
', t, or 5 = p < 0.001, 0.01, or 0.05, respectively, vs. value for rats treated with 0 ug/kg/d by Student's t test (two tailed).
Skin
Lung
Liver
25
0
25
0
25
87 ± 7`
26±3
48 ± 6"'
7 ± 0.4
62 t 10'
69
27
13
3.8
± 7"
± 3
± 1.2"
± 0.8
35±8t
10
11
ND
ND
± 1.6
± 1.2
1.2±0.3
0 3.6 ± 0.4 0.4 ± 0.06 0.8 ± 0.1
Spleen 25 204 ± 40' 92 ± 24$ 14.2 ± 5.05
0 0.07 ± 0.02 0.7 ± 0.08 0.10 ± 0.004
Glandular stomach:
Mucosa 25 50±9t
Submucosa 25 144 ± 365
J
5.9 ± 1.2 19 ± 1.35
Muscularis propria 25 32±5t
Mucosa 0 12 ± 3
Submucosa 0 45±8 3.3 ± 0.4 13 ± 1.7
Muscularis propria 0 12 ± 2
Ileum:
Mucosa 25 80 ± 145
Submucosa 25 146 ± 515 1.4 ± 0.55 508 ± 835
Muscularis propria 25 ND
Mucosa 0 38 ± 12#
Submucosa 0 19±45 0.2 ± 0.1 272 ± 5
Muscularis propria 0 ND
Table 2 . Systemic Effects of rrSCF64 on Mast Cell Populations and Tissue Mast Cell Protease Content in the Rat
Tissue rrSCF164 Mast cells RMCP I RMCP II
,ug/kg/d no.lmm2 oftissue fuglgm of tissue uglgm of tissue1. rrSCF164 treatment significantly expanded populations of
mast cellsin the mucosa, submucosa, and muscularis propria
of the glandular stomach, and in the mucosa and submucosa
of the ileum (Table 2) . MMC predominate in the mucosa
of these organs, whereas CTMC predominate in the sub-
mucosa and muscularis propria (3, 4, 24). rrSCFt64 treat-
ment increased the content of both RMCP II (p = 0.018
by the two-tailed Student's t test) and RMCP I (p = 0.045
by the one-tailed Student's t test) in the glandular stomach,
and also significantly increased the content of both proteases
in the ileum (Table 2). Thus, according to anatomical distri-
bution and mast cell protease phenotype (reviewed in refer-
ences 3-5 and 24), intravenous administration of rrSCFt64
to rats markedly expanded populations of CTMC and also
increased levels of gastrointestinal MMC.
By immunohistochemistry (24), mast cells in rrSCFtb4-
treated rats exhibited a pattern of staining for RMCP I and
II that was similar to that of mast cells in control rats (24).
For example, dermal mast cells were exclusively RMCP I+
and RMCP II - , whereas mast cells in the mucosa of the
ileum were predominantly RMCP II+ and RMCP I - .
However, the effect of rrSCF164 treatment on the numbers
of mast cells in various sites generally was more marked than
the corresponding effect on RMCP content. For example,
in the spleen, femoral bone marrow, and glandular stomach,
mast cell numbers were -3,000, 13, and 3 times those in
control rats, whereas the corresponding ratios for total con-
tent of RMCP I and II in rrSCFtb4-treated vs. control rats
were ti130, 5, and 1.5. This finding may reflect any of a
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These data (mean ± SEM) are from the same rats shown in Table 2 (see Materials and Methods).
' p < 0.001 vs . value for rats treated with 0 t~g/kg/d by Student's t test (two tailed).
number of factors, including the recent expansion of mast
cell populations in the rrSCFt64-treated animals. It is well
established that the cytoplasmic granule-associated mediator
content of rat mast cells increases progressively with the age
of the cells (reviewed in references 30 and 31).
These data show that the local injection of SCF promoted
the expansion of dermal CTMC populations in mice in vivo,
and indicate that this effect required a functionally active c-kit
receptor. In rats, intravenous administration of rrSCFt64
resulted in striking expansions of mast cell populations in
all of the anatomicalsites examined. These included sites that
usually contain large populations of CTMC, such as the skin
and peritoneal cavity, and sites that ordinarily contain sub-
stantial numbers of MMC, such as the mucosa of the glan-
dular stomach and ileum. These findings, taken together with
the observation that W/W° and Sl/Sld mice virtually lack
both CTMC and MMC (1, 2, 6), indicate that interactions
between c-kit and its ligand importantly regulate the normal
development ofboth CTMC and MMC. However, adminis-
tration of exogenous SCF not only produced significant ex-
pansions of populations of CTMC and MMC in sites or-
dinarily containing large numbers of mast cells, such as the
skin and stomach, but also resulted in the appearance of many
mast cells at sites that typically contain very few mast cells,
such as the liver, spleen, and bone marrow. These findings
raisethe possibility that the mast cell proliferation associated
with certain immunological or pathological responses may
reflect, in part, excessive local or even systemic production
of c-kit ligand.
We thank Ms. Lisa Fox and Ms. Linda Kradin for technical assistance, and Dr. Thomas Ulich for helpful
discussions.
This work was supported in part by United States Public Health Service grants AI-22674, AI-23990,
CA-28834, and GM-45311, and by AMGEN, Inc., (Thousand Oaks, CA).
Table 3. Systemic E$ects of rrSCF164 on Peritoneal and Bone Marrow Mast Cells and Mast Cell Protease Content in the Rat
Protease content of total
peritoneal cells or femoral
Cells/peritoneal cavity or femur bone marrow cells
Site rrSCF164 Total cells (107) Mast cells (106) RMCP I RMCP II
,taglkg/d ,ug ng
Peritoneal cavity 25 2.3 ± 0.1 7.6±0.5" 134±7" 17±5'
0 2.1 ± 0.2 1.7 ± 0.3 49 ± 3 0.2 ± 0.2"
Femoral bone marrow 25 9.0 ± 0.3 3.9±0.4` 34±4. 42±6'
0 8.7 ± 0.6 0.3 ± 0.1 7 ± 1 8 ± 3References
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